1009 In-depth analysis of myeloid cell subsets in lupus nephritis kidneys provides insights into disease mechanisms: lessons from the accelerating medicines partnership (AMP) in RA/SLE consortium

Benzer Materyaller

• 1009 In-depth analysis of myeloid cell subsets in lupus nephritis kidneys provides insights into disease mechanisms: lessons from the accelerating medicines partnership (AMP) in RA/SLE consortium
  Yazar:: Richard Furie, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-05-01)
• Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network
  Yazar:: Peter M. Izmirly, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-02-01)
• Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis
  Yazar:: Andrea Fava, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-01-01)
• P1012: A NUMBER OF CONGENITAL ERYTHROCYTOSIS ARE MULTIGENIC
  Yazar:: A. Benetti, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-06-01)
• 1002 Single cell transcriptomics in kidney tissue from African American patients enrolled in the accelerating medicines partnership (AMP) implicates tubular cells in the pathogenesis of APOL1 associated lupus nephritis
  Yazar:: Richard Furie, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-05-01)